Novartis disclosed seven previously unknown tumor cases in patients treated with its spinal muscular atrophy therapy, Zolgensma, following an alert publicized by SMA Europe. The drugmaker confirmed it has received a total of nine tumor reports since the treatment received approval in 2019. Medical experts and health agencies are now evaluating whether the therapy directly contributed to these malignancies. To date, Novartis has acknowledged that two of the total reported cases show evidence suggesting a possible connection to the treatment.
Key points
Evidence suggests that at least two of the reported tumor cases may be directly linked to…: Evidence suggests that at least two of the reported tumor cases may be directly linked to Zolgensma treatment.
The emergent tumor reports are currently being treated as a potential safety signal for t…: The emergent tumor reports are currently being treated as a potential safety signal for the gene therapy.
Medical professionals and patient advocacy groups are raising serious safety concerns as…: Medical professionals and patient advocacy groups are raising serious safety concerns as regulatory reviews get underway.
Sources checked by our analysis pipeline: 1
Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, a surprising development that has raised concerns among families, physicians, and patient advocacy groups.
The cases, which for the moment are being seen as only a potential safety signal, were publicized on Thursday by an advocacy group and on a Facebook page after Novartis earlier this week disclosed the information to neurologists. One advocacy group, SMA Europe, issued a statement saying that regulatory authorities are now examining the cases.
The drugmaker issued its own statement saying that since its treatment — called Zolgensma — was approved in 2019, it has received nine reports of tumors in previously treated patients. Of those, two cases to date showed evidence that the tumors may be linked to the treatment itself.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Industry lobbyists leveraged millions of dollars to shape online narratives regarding prescription drug affordability and deflect blame toward other healthcare entities. By targeting everyday health inquiries, the campaign sought to guide public understanding away from manufacturer pricing decisions during key policy debates.
State health authorities confirmed the southwestern infant fatality while maintaining privacy regarding the specific location and identity. The tragedy occurs alongside an escalating outbreak that has produced over 400 cases statewide, nearly all involving unvaccinated individuals. The incident reflects a broader national resurgence driven by immunization coverage slipping below critical herd immunity thresholds.
Widespread misconceptions lead many to treat physical decline as an unavoidable consequence of growing older, despite medical evidence that functional deterioration can start as early as age 30. Researchers emphasize that proactive lifestyle interventions, such as muscle training and social engagement, play a vital role in preventing conditions like sarcopenia. Addressing these factors early helps mitigate severe downstream health risks, including metabolic, immune, and cognitive impairments.